ArticleKidney international reports2026
IgAN and Risks of Kidney and Cardiovascular Events and Death.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Few population-based data exist in the U.S. about adults with IgA nephropathy (IgAN) and risks of kidney, cardiovascular, and mortality outcomes versus those with nonglomerular chronic kidney disease (CKD) or without CKD. Methods: We applied natural language processing (NLP) algorithms to electronic health record (EHR) data within a large integrated healthcare delivery system to identify adults with biopsy-proven IgAN between 2010 and 2020. We next identified 2 separate comparison cohorts of adults with nonglomerular CKD and adults without CKD matched on age and sex, and compared the rates of end-stage kidney disease (ESKD), worsening CKD, acute kidney injury (AKI), cardiovascular outcomes, and death through 2021 using multivariable Cox proportional hazards models. Results: We identified 1651 adults with biopsy-confirmed IgAN who had a mean age of 43 years and 48% women, 41% Asian or Pacific Islander, and 3.3% Black. Compared with matched adults with nonglomerular CKD ( Conclusion: Adults with IgAN are at greater risk of adverse kidney outcomes versus nonglomerular CKD and substantially higher risks of heart failure and death compared with no CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.